TRIMPACT: A Prospective Real-World Study of Atezolizumab Monotherapy as First-Line (Stage IV) Treatment in Patients With Non-Small Cell Lung Cancer With PD-L1 Tumor Cell Expression ≥50% and No Targetable Mutations
Status: Recruiting
Location: See all (19) locations...
Study Type: Observational
SUMMARY
This prospective, multicenter, real-world observational study aims to evaluate the clinical outcomes of first-line atezolizumab monotherapy in patients with stage IV non-small cell lung cancer (NSCLC) with PD-L1 tumor cell expression ≥50% and no targetable mutations. The study aim to determine how atezolizumab performs in routine clinical practice with respect to survival, treatment response, and safety outcomes in this patient population in Türkiye.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Signed informed consent form.
• Diagnosis of stage IV non-small cell lung cancer.
• Male or female patients aged 18 years or older.
• Patients who have been prescribed atezolizumab in accordance with routine clinical practice and the locally approved indication in Türkiye.
• Patients who have received up to 3 cycles of atezolizumab at the screening visit.
Locations
Other Locations
Turkey
Afyonkarahisar Health Sciences University Hospital
RECRUITING
Afyonkarahisar
Ankara Bilkent City Hospital
NOT_YET_RECRUITING
Ankara
Ankara Oncology Training and Research Hospital
NOT_YET_RECRUITING
Ankara
Memorial Ankara Hospital
NOT_YET_RECRUITING
Ankara
Antalya Training and Research Hospital
RECRUITING
Antalya
Adnan Menderes University Faculty of Medicine Hospital
RECRUITING
Aydin
Dicle University Hospital
NOT_YET_RECRUITING
Diyarbakır
Trakya University Faculty of Medicine Hospital
RECRUITING
Edirne
Bahçelievler Memorial Hospital
NOT_YET_RECRUITING
Istanbul
İstanbul Medipol Mega Hospital
NOT_YET_RECRUITING
Istanbul
Marmara Üniversitesi Pendik Eğitim ve Araştırma Hastanesi
NOT_YET_RECRUITING
Istanbul
Ümraniye Training and Research Hospital
NOT_YET_RECRUITING
Istanbul
Dokuz Eylul University Faculty of Medicine Hospital
RECRUITING
Izmir
Necmettin Erbakan University Meram Faculty of Medicine Hospital
RECRUITING
Konya
Mersin University Faculty of Medicine Hospital
RECRUITING
Mersin
Ordu State Hospital
NOT_YET_RECRUITING
Ordu
Sakarya University Faculty of Medicine Hospital
RECRUITING
Sakarya
Medical Park Samsun Hospital
NOT_YET_RECRUITING
Samsun
Karadeniz Technical University Farabi Hospital
RECRUITING
Trabzon
Contact Information
Primary
Derya Kıvrak Salim
derya.kivraksalim@sbu.edu.tr
+90 533 648 82 17
Time Frame
Start Date:2025-09-15
Estimated Completion Date:2027-10-01
Participants
Target number of participants:150
Treatments
Atezolizumab Real-World Cohort
This observational cohort consists of patients with stage IV non-small cell lung cancer (NSCLC) who receive first-line atezolizumab in routine clinical practice. Participants are included based on real-world treatment decisions made by their physicians, and no study-mandated interventions or procedures are required. The cohort reflects patients treated according to local standards of care, allowing evaluation of real-life treatment patterns, clinical outcomes, and safety in this population.